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In the current pathophysiological model of chronic ischemic heart disease (IHD), myocardial ischemia and exer-
tional angina are caused by obstructive atherosclerotic plaque, and the clinical management of IHD is centered
on the identification and removal of the stenosis. Although this approach has been in place for years, several
lines of evidence, including poor prognostic impact, suggest that this direct relationship may present an oversim-
plified view of IHD. Indeed, a large number of studies have found that IHD can occur in the presence or absence
of obstructive coronary artery disease and that atherosclerosis is just 1 element in a complex multifactorial
pathophysiological process that includes inflammation, microvascular coronary dysfunction, endothelial dysfunc-
tion, thrombosis, and angiogenesis. Furthermore, the high recurrence rates underscore the fact that removing
stenosis in patients with stable IHD does not address the underlying pathological mechanisms that lead to the
progression of nonculprit lesions. The model proposed herein shifts the focus away from obstructive epicardial
coronary atherosclerosis and centers it on the microvasculature and myocardial cell where the ischemia is tak-
ing place. If the myocardial cell is placed at the center of the model, all the potential pathological inputs can be
considered, and strategies that protect the cardiomyocytes from ischemic damage, regardless of the causative
mechanism, can be developed. (J Am Coll Cardiol 2012;60:951–6) © 2012 by the American College of Cardi-
ology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.082In 1974, Gould and Lipscomb (1) described the effects of
progressive coronary artery narrowing on resting and max-
imal coronary blood flow. A reduction in coronary artery
diameter of 50% limited maximal coronary vasodilative
capacity and a reduction of 85% limited resting coronary
blood flow. These laboratory findings were soon transposed
into the clinical setting, in which obstructive atherosclerosis
50% was defined as hemodynamically significant coronary
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2012, accepted February 28, 2012.stenosis and 85% as critical coronary stenosis (2). The
concept of “critical coronary stenosis” was then further
transmuted into “ischemia-causing stenosis.” On the basis
of this chain of postulates, coronary stenosis, and therefore
atherosclerotic obstructions, gained increasing recognition
as a consistent cause of ischemic heart disease (IHD). Thus,
when a relatively simple percutaneous technique that could
reduce the atherosclerotic obstruction was introduced (3),
the cardiology community reacted with great enthusiasm
and promptly endorsed the method.
See page 957
However, after the performance of hundreds of thousands
of these procedures worldwide, outcome analysis does not
support the initial enthusiasm, except for opening of acutely
occluded arteries in patients with ST-segment elevation
myocardial infarction (STEMI). Several lines of evidence
suggest that the direct relationship between chronic ob-
structive coronary atherosclerosis and IHD has been taken
for granted and may represent an overly simplified view of
IHD. Many patients with evidence of myocardial ischemia
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erosclerosis at angiography, and
conversely, some patients with
severe coronary atherosclerotic
obstructions neither experience
chest pain nor present with any
evidence of myocardial ischemia
(4,5). Furthermore, in a large
fraction of patients having un-
dergone coronary revasculariza-
tion, myocardial ischemia per-
sists or reoccurs after a short time
interval, and overall elective re-
duction or bypass of the stenosis
has little impact on prognosis (6–14). These inconsistencies
between theory and clinical reality should strongly encour-
age us to question carefully the assumption that there is a
1-to-1 relationship between severity of atherosclerotic ob-
struction and IHD and to review the data supporting the
idea that IHD is a complex multifactorial condition.
Despite Current Practices, Coronary Artery
Disease and IHD Are Not Consistently Associated
In clinical practice, the perception that there is a 1-to-1
causal relationship between obstructive coronary artery dis-
ease (CAD) and IHD has led to IHD and CAD becoming
essentially synonymous. The diagnosis of IHD in a patient
who has angina and myocardial ischemia is only accepted if
significant coronary atherosclerotic obstruction can be iden-
tified at coronary angiography. A similar patient with
comparable evidence of ischemia, but no atherosclerotic
obstruction at coronary angiography, is generally regarded
with suspicion or dismissed. Similarly, sensitivity and spec-
ificity of provocative tests are established based on the
presence or absence of coronary atherosclerosis and, hence,
not on the evidence of myocardial ischemia. As a result,
diagnosis, prevention, and treatment of IHD are centered
on the presence and severity of coronary atherosclerotic
obstructions (15).
However, the concept of coronary atherosclerotic steno-
ses being necessary and sufficient to cause myocardial
ischemia does not hold up to scrutiny. In fact, extensive data
have failed to show that all patients who have atherosclerotic
obstructions have IHD or, conversely, that all patients who
have IHD present with obstructive coronary atherosclerosis.
In a cohort of 163 symptomatic patients, Lin et al. (16)
found that 39 patients presented with obstructive CAD and
105 with nonobstructive lesions. Of note, 15 of the 39
patients with flow-limiting lesions presented with normal
stress test results for ischemia.
Although the atherosclerotic process often progresses
toward flow-limiting stenosis, most patients die of an acute
coronary syndrome, commonly attributed to ruptured
Abbreviations
and Acronyms
CAD  coronary artery
disease
FFR  fractional flow
reserve
IHD  ischemic heart
disease
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionplaques, rather than progressive stenosis (17).To further complicate the subject, in an autopsy study of
young adults who died as a result of accidents, homicides,
and suicides, 60% of men had American Heart Association
grade 2 or higher left anterior descending plaques but had
never experienced IHD (18). Because the incidence of
angina pectoris is estimated to remain 30% in older (65
years of age) Western populations, it is likely that a large
number of these young men would never have developed
IHD (19,20). Another pathology series showed that al-
though critical coronary stenosis was present in 90% of
patients with acute and chronic IHD, it also reached 50% in
control subjects with no history of IHD (21). Thrombosis,
which was the principal characteristic of acute unstable
ischemic syndromes, was also found in 12% of patients with
stable angina, 14% of patients with ischemic cardiomyopa-
thy, and 4% of control subjects. In a 1980 study of 212
consecutive patients with acute coronary syndrome, coro-
nary angiographic and electrocardiographic data showed
that 30.6% of patients had normal or near-normal vessels
(22). Similarly, in the large GUSTO IIb (Global Use of
Strategies to Open Occluded Coronary Arteries in Acute
Coronary Syndromes IIb) study of patients with acute
coronary syndromes (N  12,142), 30.5% of women with
unstable angina and 10.2% of women with STEMI had
normal coronary angiographies (Fig. 1) (23).
These data thus underscore the fact that the 1-to-1
assumption which cardiologists have become accustomed to
is too narrow, as IHD may be present with or without
obstructive CAD. Thus, the presence or absence of coronary
atherosclerotic obstructions is of limited relevance to the
diagnosis and treatment of IHD.
Removing Stenoses
Does Not Consistently Treat IHD
The “plaque-centric” hypothesis can also be called into
question when the impact of therapeutic strategies based on
Figure 1 Percentage of Patients Who Had IHD But Not CAD
The percentage of patients who had ischemic heart disease (IHD) but no coro-
nary artery disease (CAD) varied from 4% to 30% depending on clinical presen-
tation (myocardial infarction [MI] with ST-segment elevation, MI with no ST-segment
elevation, and unstable angina) and sex. Total number of patients was 6,406.
Adapted, with permission, from Hochman et al. (23).
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considered. Most reports agree that, on top of medical
therapy, revascularization improves symptoms, but in many
patients angina recurs after 2 to 3 years, and myocardial
infarction and death are not prevented. In the COURAGE
(Clinical Outcomes Utilizing Revascularization and Ag-
gressive Drug Evaluation) trial (N  2,287), which evalu-
ated percutaneous coronary intervention (PCI) on top of
medical therapy, 30% of patients were still symptomatic
ith angina 1 year after PCI (7). Interestingly, the incidence
f angina was not significantly different from that in patients
ho did not undergo a revascularization procedure (Fig. 2).
oreover, no significant between-group differences were
oted for the composite endpoint (death, myocardial infarc-
ion, and stroke), all-cause mortality, hospitalization for
cute coronary syndrome, or myocardial infarction.
The pathophysiological relevance of obstructive lesions in
he genesis of IHD was further elucidated in the FAME
Fractional Flow Reserve versus Angiography for Multives-
el Evaluation) study, in which 1,005 patients who had
ultivessel CAD were randomly assigned to undergo PCI
ith implantation of drug-eluting stents guided by using
ngiography alone or guided by using fractional flow reserve
FFR) measurements in addition to angiography (24).
atients assigned to FFR-guided PCI underwent stenting
f indicated lesions only if FFR was 0.80, whereas those
ssigned to angiography-guided PCI underwent stenting of
ll angiographically significant lesions. The 1-year event rate
as 18.3% in the angiography group and 13.2% in the FFR
roup (p  0.02). Importantly, 78% of patients in the
ngiography group were free of angina at 1 year, compared
ith 81% of patients in the FFR group (p  0.20). These
esults further support the notion that not all obstructive
therosclerotic lesions produce ischemia, the key principle
f the obstructive CAD-IHD paradigm.
Figure 2 Rate of Angina After PCI in the COURAGE Trial
Compared with baseline, angina rates (median  SEs) decreased in both
groups. Significant differences between treatment groups were noted at the
1- and 3-year time points but not at baseline or at 5 years. PCI  percutane-
ous coronary intervention. COURAGE  Clinical Outcomes Utilizing Revascu-
larization and Aggressive Drug Evaluation. Adapted, with permission, from
Boden et al. (7).oIn addition, a recent study (N  1,212) found that even
n patients who have obstructive CAD and heart failure,
here was no significant difference in all-cause mortality
etween patients in the medical therapy group and those in
he medical therapy plus coronary artery bypass grafting
roup (25). Such results are not groundbreaking: large
linical trials have consistently shown a lack of mortality
enefit and a significant percentage of patients presenting
ith angina and positive stress test results after coronary
evascularization (8–14).
These disappointing results for symptom control after
oronary revascularization have been attributed to a number
f factors, including incomplete revascularization, in-stent
estenosis, and patient-related factors. However, in a highly
elected cohort of 220 patients in whom all possible con-
ounding factors had been excluded, one third of patients
ere symptomatic with angina and presented with a positive
xercise stress test result 1 month after the index procedure
6). In the BARI (Bypass Angioplasty Revascularization
nvestigation) study (N  407), 5 years after revasculariza-
ion, jeopardized myocardium and angina recurrence oc-
urred more often due to obstructive CAD progression in
reviously untreated arteries than to failed revascularization
f the baseline hemodynamically significant lesions (10).
oreover, it has recently been reported that PCI, in the
etting of acute coronary syndromes, does not prevent
ecurrence of ischemic events at the culprit lesion, as in the
ROSPECT (Providing Regional Observations to Study
redictors of Events in the Coronary Tree) trial (N  697)
9). In that trial, 20.4% of patients had a recurrent major
ardiovascular event within 3 years of a successful PCI.
oughly one half of these events were attributable to lesions
hat had been originally assessed as nonculprit lesions and
ere angiographically mild at baseline, whereas the other
alf occurred at the site of the previously stented culprit
esions.
These studies certainly do not deny the usefulness of
evascularization in evidence-based situations such as STEMI,
ut they do raise questions about whether revascularization
hould continue to be regarded as the definitive treatment for
HD. The unchanged prognosis and the high recurrence rate
learly suggest that revascularization procedures remove the
therosclerotic obstructions but do not cure the underlying
isease.
HD as a Complex Pathophysiological Process
he pathophysiological events that occur at the coronary
therosclerotic plaque have been of great interest for the past
ew decades. As classically described in textbooks, fatty
laque progressively builds up to obstructive atherosclerotic
laque, causing myocardial ischemia and angina. At any
tage of this progression, plaque rupture, fissure, or erosion
ay lead to thrombotic occlusion and precipitate acute
oronary syndromes (26). However, obstructive plaque is
nly 1 of the manifestations of atherosclerotic disease.
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including “spontaneous” thrombosis, coronary vasospasm,
inflammation, microvascular dysfunction, endothelial dys-
function, and angiogenesis, have been shown to be capable
of precipitating myocardial ischemia (27–29).
In a series of 132 autopsies of hearts from patients who
died of noncardiac causes, coronary thrombi were shown to
overlay the intima of a coronary vessel independently of
plaque type and severity (27). Endothelial dysfunction,
which has been shown to play an important role in the
development of IHD through its regulation of vascular tone,
platelet activity, leukocyte adhesion, and thrombosis, is a
predictor of IHD in patients with and without obstructive
CAD (30–32). In a study of 308 patients undergoing
cardiac catheterization, acute cardiovascular events were
independently predicted on the basis of epicardial and
microvascular coronary endothelial dysfunction both in
patients with angiographically normal coronary arteries and
in patients with obstructive CAD (32). Inflammation is also
a prominent part of the pathological process. Monocyte-
derived macrophages and T lymphocytes produce and se-
crete mediator molecules, such as cytokines, chemokines,
growth factors, enzymes, and disintegrins, which activate
endothelial cells, increase vasoreactivity, and cause prolifer-
ation of smooth muscle cells and lesion progression (30). In
articular, plasma C-reactive protein has been shown to
e a risk factor for IHD in IHD-free middle-aged men
nd has been detected in patients with angina regardless
f the presence of obstructive lesions (33,34). Lastly,
asomotor response, which has traditionally been consid-
red to be a precursor of atherosclerosis, has now been
hown to be an independent predictor of IHD in women
ith no or minimal epicardial stenosis and suspected
schemia (35).
Women represent a patient population in whom the
ttributes of IHD as a multifactorial disease are most clearly
epresented (28). In fact, while presenting with a lower
oronary atherosclerotic burden, the morbidity and mortal-
ty of IHD in women are similar to those in men (36). The
orbidity and mortality associated with the disease in this
atient subset have been a driving force in the exploration of
ther causes of myocardial ischemia. In line with these
onsiderations, microvascular coronary dysfunction in
hronic angina is almost considered a disease of the female
ex.
Thus, a large amount of evidence supports the concept
hat obstructive atherosclerosis is neither a sufficient nor
necessary cause for IHD but just 1 component of a
omplex pathophysiological process. Although these
athways are barely taken into consideration in clinical
ractice, several alternative causes of IHD are listed in
he universal definition of myocardial infarction (37) as
ell as in a recent update of acute coronary syndrome
uidelines (38).Calling for a Copernican Revision
Given the inconsistencies associated with the obstructive
“plaque-centric” approach, a shift in the paradigm that takes
into consideration the multifactorial aspect of IHD seems
warranted. Our attention should be focused on the micro-
vasculature with resultant myocardial ischemia and on the
myocardial cell. If we put the myocardial cell at the center of
the model, all the potential pathological inputs that might
drive progression to unstable angina, acute myocardial
infarction, and sudden cardiac death can be considered,
starting with obstructive atherosclerosis but also including
inflammation, endothelial dysfunction, microvascular dys-
function, platelet dysfunction, thrombosis, and vasomotor
dysfunction (Fig. 3).
Accordingly, we should adopt diagnostic and therapeutic
strategies focused on myocardial ischemia rather than on
obstructive coronary atherosclerosis. FFR is a valuable
invasive tool for the assessment of the hemodynamic effects
of epicardial vessel obstructions. Time to ST-segment
depression during exercise, degree and extension of ST-
segment depression, severity, and extension of perfusion
defects at myocardial imaging may provide a noninvasive
evaluation of myocardial ischemia that should not be denied
in the absence of significant stenosis (i.e., “false-positive”
results) or taken for granted in the presence of significant
stenosis (i.e., “false-negative” results).
In daily practice, such a shift in focus could imply either
identifying mechanisms responsible for ischemia and
applying a specific treatment in each patient or develop-
ing strategies that can protect the cardiomyocytes from
ischemic damage, regardless of the causative mechanism
(39,40).
Figure 3 Proposed Paradigm Shift in IHD
The proposed shift in paradigm (“the solar system of ischemic heart disease
[IHD]”) puts myocardial ischemia at the center of our approach and critical cor-
onary stenosis on the side as 1 of many contributors to myocardial ischemia.
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September 11, 2012:951–6 Coronary Stenosis and Myocardial Ischemia: Re-Examining the LinkConclusions
A large body of evidence conclusively suggests that coronary
artery obstruction is only 1 element in a complex multifac-
torial pathophysiological process that leads to IHD and that
the presence of obstructive lesions in patients with IHD
does not necessarily imply a causative role. A more com-
prehensive approach seems necessary to refocus preventive
and therapeutic strategies and to decrease morbidity and
mortality. To this effect, we propose a shift in approach
to include the myocardial cell as well as the coronary
vessel.
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